Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK Biobank project cleared for national rollout
Following a three-month piloting phase in the Manchester area, the final protocol received unanimous backing from a team of international scientific and medical experts, and from the project’s
Following a three-month piloting phase in the Manchester area, the final protocol received unanimous backing from a team of international scientific and medical experts, and from the project’s
Twinject, a novel epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions (anaphylaxis), was launched in the US and Canada in 2005. It is the first
Quigley Pharma filed the patent application based upon observations that subjects participating in a proof of concept study using QR-333 had further improvements over and above the existing
Under the terms of the agreement, Human Genome Sciences spin-off CoGenesys will receive an upfront licensing fee, and is entitled to development milestone payments and royalties based on
Antara (fenofibrate) is part of the $22 billion US market for treating dyslipidemias, which includes the $1 billion fenofibrate market. It is indicated as an adjunct treatment for
ATG003 is a proprietary topical formulation of mecamylamine that has shown efficacy in animal models and is a possible alternative to current therapies for age-related macular degeneration (AMD),
The study has begun enrollment in approximately 130 centers across the US. It aims to study how the implementation of regularly scheduled interferon beta (IFN-beta) neutralizing antibody (NAb)
RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. Since many diseases are caused by the inappropriate activity of
Dynavax’ flu vaccine is based on the company’s proprietary TLR-9 agonist-based immunostimulatory sequence (ISS) technology and is specifically designed to overcome the limitations of both development-stage pandemic vaccines
Israel-headquartered Teva’s Azilect (rasagiline tablets) is approved for use as initial monotherapy in early Parkinson’s disease and as adjunct therapy to levodopa in moderate to advanced disease. The